Detalhe da pesquisa
1.
Durable response after tisagenlecleucel in adults with relapsed/refractory follicular lymphoma: ELARA trial update.
Blood
; 143(17): 1713-1725, 2024 Apr 25.
Artigo
em Inglês
| MEDLINE | ID: mdl-38194692
2.
A randomized phase 3 trial of autologous vs allogeneic transplantation as part of first-line therapy in poor-risk peripheral T-NHL.
Blood
; 137(19): 2646-2656, 2021 05 13.
Artigo
em Inglês
| MEDLINE | ID: mdl-33512419
3.
General condition and comorbidity of long-term survivors of adult acute lymphoblastic leukemia.
Haematologica
; 108(7): 1758-1767, 2023 Jul 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-36779593
4.
A phase II trial to evaluate the combination of pixantrone and obinutuzumab for patients with relapsed aggressive lymphoma: Final results of the prospective, multicentre GOAL trial.
Br J Haematol
; 198(3): 482-491, 2022 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-35362552
5.
Reinduction therapy with everolimus in combination with dexamethasone, high-dose cytarabin and cisplatinum in patients with relapsed or refractory classical Hodgkin lymphoma: an experimental phase I/II multicentre trial of the German Hodgkin Study Group (GHSG HD-R3i).
Br J Haematol
; 196(3): 606-616, 2022 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-34775591
6.
Targeting CD19 in diffuse large B-cell lymphoma: An expert opinion paper.
Hematol Oncol
; 40(4): 505-517, 2022 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-35488888
7.
90-yttrium-ibritumomab tiuxetan as first-line treatment for follicular lymphoma: updated efficacy and safety results at an extended median follow-up of 9.6 years.
Ann Hematol
; 101(4): 781-788, 2022 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-35150296
8.
Antibody-mediated procoagulant platelets in SARS-CoV-2-vaccination associated immune thrombotic thrombocytopenia.
Haematologica
; 106(8): 2170-2179, 2021 08 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-34011137
9.
A phase II study of the PI3K inhibitor copanlisib in combination with the anti-CD20 monoclonal antibody rituximab for patients with marginal zone lymphoma: treatment rationale and protocol design of the COUP-1 trial.
BMC Cancer
; 21(1): 749, 2021 Jun 29.
Artigo
em Inglês
| MEDLINE | ID: mdl-34187401
10.
Four versus six cycles of CHOP chemotherapy in combination with six applications of rituximab in patients with aggressive B-cell lymphoma with favourable prognosis (FLYER): a randomised, phase 3, non-inferiority trial.
Lancet
; 394(10216): 2271-2281, 2019 12 21.
Artigo
em Inglês
| MEDLINE | ID: mdl-31868632
11.
Genomic CDKN2A/2B deletions in adult Ph+ ALL are adverse despite allogeneic stem cell transplantation.
Blood
; 131(13): 1464-1475, 2018 03 29.
Artigo
em Inglês
| MEDLINE | ID: mdl-29348129
12.
Phase I dose escalation study of BI 836826 (CD37 antibody) in patients with relapsed or refractory B-cell non-Hodgkin lymphoma.
Invest New Drugs
; 38(5): 1472-1482, 2020 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-32172489
13.
Oncological outcome and recurrence pattern analysis after involved-field irradiation in combination with rituximab for early-stage nodal and extranodal follicular lymphoma.
Strahlenther Onkol
; 196(8): 705-714, 2020 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-32377821
14.
Concepts in immuno-oncology: tackling B cell malignancies with CD19-directed bispecific T cell engager therapies.
Ann Hematol
; 99(10): 2215-2229, 2020 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-32856140
15.
Phase II trial evaluating the efficacy and safety of the anti-CD20 monoclonal antibody obinutuzumab in patients with marginal zone lymphoma.
Future Oncol
; 16(13): 817-825, 2020 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-32223334
16.
[Perspectives on CAR T-cell treatment]. / Perspektiven der CAR-T-Zell-Therapie.
Pathologe
; 41(Suppl 2): 149-154, 2020 Dec.
Artigo
em Alemão
| MEDLINE | ID: mdl-33113044
17.
Doubling rituximab in high-risk patients with aggressive B-cell lymphoma -results of the DENSE-R-MegaCHOEP trial.
Br J Haematol
; 184(5): 760-768, 2019 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-30520013
18.
Phase 2 study of the bispecific T-cell engager (BiTE) antibody blinatumomab in relapsed/refractory diffuse large B-cell lymphoma.
Blood
; 127(11): 1410-6, 2016 Mar 17.
Artigo
em Inglês
| MEDLINE | ID: mdl-26755709
19.
PI3Kδ inhibition by idelalisib in patients with relapsed indolent lymphoma.
N Engl J Med
; 370(11): 1008-18, 2014 Mar 13.
Artigo
em Inglês
| MEDLINE | ID: mdl-24450858
20.
Long-term survival and T-cell kinetics in relapsed/refractory ALL patients who achieved MRD response after blinatumomab treatment.
Blood
; 126(24): 2578-84, 2015 Dec 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-26480933